Delivery technologies to engineer natural killer cells for cancer immunotherapy

Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering

(2020) Margaret M. Billingsley et al.   NANO LETTERS

The therapeutic landscape for cells engineered with chimeric antigen receptors

(2020) Matthew MacKay et al.   NATURE BIOTECHNOLOGY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy

(2020) Xianwu Wang et al.   ACS Central Science

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy

(2020) Aline Pfefferle et al.   Cancers

Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?

(2020) Laura Damele et al.   Cancers

Natural Killer Cells: Tumor Surveillance and Signaling

(2020) Lizeth G. Meza Guzman et al.   Cancers

Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies

(2020) Keerthana Shankar et al.   Stem Cell Research & Therapy

Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands

(2020) Zubao Gan et al.   Bioengineering & Translational Medicine

Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy

(2020) Nour Shobaki et al.   JOURNAL OF CONTROLLED RELEASE

CAR-NK cells: A promising cellular immunotherapy for cancer

(2020) Guozhu Xie et al.   EBioMedicine

Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy

(2020) Senlian Hong et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Engineering precision nanoparticles for drug delivery

(2020) Michael J. Mitchell et al.   NATURE REVIEWS DRUG DISCOVERY

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

(2019) Jianguang Zhang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Delivery technologies for cancer immunotherapy

(2019) Rachel S. Riley et al.   NATURE REVIEWS DRUG DISCOVERY

Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection

(2019) Yang-Ding Lin et al.   Frontiers in Immunology

Recent Advances in Cancer Stem Cell-Targeted Immunotherapy

(2019) Narayanasamy Badrinath et al.   Cancers

Nanoparticles for Nucleic Acid Delivery: Applications in Cancer Immunotherapy

(2019) Alvin J. Mukalel et al.   CANCER LETTERS

Target selection for CAR-T therapy

(2019) Jianshu Wei et al.   Journal of Hematology & Oncology

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy

(2019) Kyle B. Lupo et al.   Cancers

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

(2019) Emily J. Pomeroy et al.   MOLECULAR THERAPY

Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions

(2019) Stephen J. Bagley et al.   PHARMACOLOGY & THERAPEUTICS

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

(2019) Michael C. Burger et al.   Frontiers in Immunology

Engineered materials for in vivo delivery of genome-editing machinery

(2019) Sheng Tong et al.   Nature Reviews Materials

Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells

(2019) L. Herrera et al.   Scientific Reports

Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy

(2018) Pedro P.G. Guimarães et al.   ACS Nano

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering

(2018) May Daher et al.   CURRENT OPINION IN IMMUNOLOGY

Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters

(2018) Colin J. McKinlay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

(2018) Rohtesh S. Mehta et al.   Frontiers in Immunology

Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies

(2018) Sandro Matosevic   Journal of Immunology Research

Allogeneic CAR-T Cells: More than Ease of Access?

(2018) Charlotte Graham et al.   Cells

Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21

(2017) Maria A. Streltsova et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers

(2017) Elizabeth L. Siegler et al.   MOLECULAR THERAPY

Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene

(2017) Zhang-Hui Chen et al.   NATURE BIOTECHNOLOGY

Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet

(2017) P.E. Bunney et al.   PHYSIOLOGY & BEHAVIOR

Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals

(2017) Colin J. McKinlay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics—An innate immune system standpoint

(2017) Yasmin Granot et al.   SEMINARS IN IMMUNOLOGY

Natural killer cell-mediated immunosurveillance of human cancer

(2017) Karl-Johan Malmberg et al.   SEMINARS IN IMMUNOLOGY

In situ click chemistry generation of cyclooxygenase-2 inhibitors

(2017) Atul Bhardwaj et al.   Nature Communications

FDA Approves Second CAR T-cell Therapy

(2017)   Cancer Discovery

First-Ever CAR T-cell Therapy Approved in U.S.

(2017)   Cancer Discovery

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

(2017) John P. Veluchamy et al.   Frontiers in Immunology

Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation

(2016) Brian C. Shaffer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Super natural killer cells that target metastases in the tumor draining lymph nodes

(2016) Siddarth Chandrasekaran et al.   BIOMATERIALS

TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer

(2016) Elizabeth C. Wayne et al.   JOURNAL OF CONTROLLED RELEASE

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

(2016) Caroline Jochems et al.   Oncotarget

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

(2016) Xilin Chen et al.   Oncotarget

Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

(2016) Y. Yang et al.   Cancer Immunology Research

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

Chimeric antigen receptor T-cell therapy for solid tumors

(2016) Kheng Newick et al.   Molecular Therapy-Oncolytics

Adoptive cellular therapy: A race to the finish line

(2015) Carl H. June et al.   Science Translational Medicine

Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer

(2015) David L. Hermanson et al.   STEM CELLS

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications

(2015) Mattias Carlsten et al.   Frontiers in Immunology

CRISPR-Cas systems for editing, regulating and targeting genomes

(2014) Jeffry D Sander et al.   NATURE BIOTECHNOLOGY

Enhanced Cytotoxicity of Natural Killer Cells following the Acquisition of Chimeric Antigen Receptors through Trogocytosis

(2014) Fu-Nan Cho et al.   PLoS One

TRAIL-coated leukocytes that kill cancer cells in the circulation

(2014) M. J. Mitchell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

RNA Interference by Single- and Double-stranded siRNA With a DNA Extension Containing a 3′ Nuclease-resistant Mini-hairpin Structure

(2014) Simon J Allison et al.   Molecular Therapy-Nucleic Acids

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Natural killer cell deficiency

(2013) Jordan S. Orange   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

(2013) Hua Jiang et al.   Molecular Oncology

Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand

(2013) Kyohei Nakamura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct roles of NK cells in viral immunity during different phases of acute Friend retrovirus infection

(2013) Elisabeth Littwitz et al.   Retrovirology

Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

(2013) David A. Knorr et al.   Stem Cells Translational Medicine

Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7

(2012) S. S. Somanchi et al.   BLOOD

A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies

(2012) Noriko Shimasaki et al.   CYTOTHERAPY

Optimization of the Transductional Efficiency of Lentiviral Vectors: Effect of Sera and Polycations

(2012) Warren Denning et al.   MOLECULAR BIOTECHNOLOGY

The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation

(2011) Martha Luevano et al.   HUMAN IMMUNOLOGY

NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin

(2011) Ruth Esser et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

(2011) Laurent Boissel et al.   LEUKEMIA & LYMPHOMA

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

(2010) J. A. Olson et al.   BLOOD

Allogeneic natural killer cells for refractory lymphoma

(2010) Veronika Bachanova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method

(2009) L Li et al.   CANCER GENE THERAPY

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients

(2008) Steven J. Howe et al.   JOURNAL OF CLINICAL INVESTIGATION

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

(2008) Salima Hacein-Bey-Abina et al.   JOURNAL OF CLINICAL INVESTIGATION